Revaccination with measles, tetanus, poliovirus, Haemophilus influenzae type B, meningococcus C, and pneumococcus vaccines in children after hematopoietic stem cell transplantation

Clinical Infectious Diseases

Volumn 44, Issue 5, 2007, Pages 625-634

  Patel, Soonie R ^a,f   Ortín, Miguel ^a   Cohen, Bernard J ^b   Borrow, Ray ^e   Irving, Diane ^c   Sheldon, Joanne ^c   Heath, Paul T ^d  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c St Georges Hospital

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPLOID CELL VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; MMR II; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY BLOOD LEVEL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CHILD; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; MALE; MEASLES; POLIOMYELITIS; PRIORITY JOURNAL; REVACCINATION; STREPTOCOCCUS INFECTION; TETANUS;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; HAEMOPHILUS VACCINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MEASLES VACCINE; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINES; TETANUS TOXOID; VACCINES;

EID: 33847056683     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/511641     Document Type: Article

References (39)

1. Shiobara S, Harada M, Mori T, et al. Difference in post-transplant recovery of immune reactivity between allogeneic and autologous bone marrow transplant. Transplant Proc 1982; 14:429-33.
2. de Vries E, Van Tol MJD, Langlois van den Bergh R, et al. Reconstitution of lymphocyte subpopulations after paediatric bone marrow transplantation. Bone Marrow Transplant 2000; 25:267-75.
3. Witherspoon RP, Storb R, Ochs HD, et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time post transplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 1981; 58:360-8.
4. Lum LG. The kinetics of immune reconstitution after human marrow transplantation. Blood 1987; 69:369-80.
5. Foot AB, Potter MN, Donaldson C, et al. Immune reconstitution after BMT in children. Bone Marrow Transplant 1993; 11:7-13.
6. Fallen PR, McGreavey L, Madrigal JA, et al. Factors affecting reconstitution of the T cell compartment in allergenic haematopoietic cell transplant recipients. Bone Marrow Transplant 2003; 32:1001-14.
7. Hammarström V, Pauksen K, Svensson H, et al. Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients. Transplantation 2000; 69:1582-6.
8. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps and rubella vaccine. J Infect Dis 1989; 159:610-5.
9. Spoulou V, Giannaki M, Vounatsou M, Bakoula C, Grafakos S. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants. Bone Marrow Transplant 2004; 33:1187-90.
10. Ljungman P, Duraj V, Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 1991; 7:89-93.
11. Pauksen K, Hammarström V, Ljungman P, et al. Immunity to poliovirus and immunisation with inactivated poliovirus vaccine after autologous bone marrow transplantation. Clin Infect Dis 1994; 18:547-52.
12. Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Response to tetanus toxoid immunisation after allogeneic bone marrow transplantation. J Infect Dis 1990; 162:496-500.
13. Parkkali T, Olander R-M, Ruutu T, et al. A randomised comparison between early and late vaccination with tetanus toxoid vaccine in allogeneic BMT. Bone Marrow Transplant 1997; 19:933-8.
14. Winston DJ, Ho WG, Schiffman G, Champlin RE, Feig SA, Gale RP. Pneumococcal vaccination of recipients of bone marrow transplants. Arch Intern Med 1983; 143:1735-7.
15. Vance E, George S, Guinan EC, et al. Comparison of multiple immunization schedules for Haemophilus influenzae type b-conjugate and tetanus toxoid vaccines following bone marrow transplantation. Bone Marrow Transplant 1998; 22:735-41.
16. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 1994; 57:677-84.
17. Ljungman P, Cordonnier C, de Bock R, et al. Immunisations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European group for blood and marrow transplantation. Bone Marrow Transplant 1995; 15:455-60.
18. Royal College of Paediatrics and Child Health (RCPCH). Immunisation of the immunocompromised child: best practice statement. RCPCH, 2002:10-3.
19. Ljungman P, Engelhard D, Cámara R de la, et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 2005; 35:737-46.
20. Albrecht P, van Steenis G, van Wezel AL, SaIk JE. Standardization of poliovirus neutralizing antibody tests. Rev Infect Dis 1984; 6(Suppl 2): S540-4.
21. Markowitz LE, Sepulveda J, Diaz-Ortega JL, et al. Immunisation of six-month-old infants with different doses of Edmonston-Zagreb and Schwarz measles vaccines. N Engl J Med 1990; 322:580-7.
22. Maslanka SE, Gheesling LL, LiButti DE, et al. Standardization and a multi-laboratory comparison of Neisseria Meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67.
23. Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a monoplex assay for the simultaneous quantitation of antibodies to 9 Streptococcus pneumoniae serotypes. J Immunol Methods 2005; 296:135-47.
24. Käythy H, Peltola H, Karanko V, Mäkelä P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100-3.
25. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75.
26. Borrow R, Andrews N, Goldblatt D, Miller E. Serological basis for the use of meningococcal sergroup C conjugate vaccines in the United Kingdom: re-evaluation of correlates of protection. Infect Immun 2001; 69:1568-73.
27. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine using efficacy estimates from post-licensure surveillance in England. Clin Diag Lab Immunol 2003; 10:780-6.
28. World Health Organization, Expert Committee on Biological Standardization. Pneumococcal conjugate vaccines: recommendations for production and quality control of pneumococcal conjugate vaccines. 2003. Available at: http://www.who.int/biologicals/Pneumococcal_ Conjugate_Vaccines_Recomm_Nov_2003. Accessed July 2004.
29. Johnson N, Ruggeberg JU, Balfour GF, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006; 12:937-41.
30. Black SB, Shinefield HR, Lampert D, et al. Safety and immunogenicity of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in infancy. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Pediatr Infect Dis J 1991; 10:92-6.
31. Balmer P, Falconer M, McDonald P, et al. Immune response to meningococcal serogroup C vaccine in asplenic individuals. Infection and Immunity 2004; 72:332-7.
32. Richmond P, Borrow R, Miller E, et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179:1569-72.
33. Fairley CK, Begg N, Borrow R, Fox AJ, Jones DM, Cartwright K. Conjugate meningococcal serogroup A and C vaccine: reactogenecity and immunogenicity in United Kingdom infants. J Infect Dis 1996; 174:1360-3.
34. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunised at age 6 months. JAMA 1998; 280:527-32.
35. Machado CM, de Souza VAUF, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. Bone Marrow Transplant 2005; 35:787-91.
36. Overturf GD and the Committee on Infectious Diseases. American Academy of Pediatrics. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis. Pediatrics 2000; 106:367-76.
37. Lin PL, Michaels MG, Green M, et al. Safety and immunogenicity of the American Academy of Pediatrics-recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients. Pediatrics 2005; 116:160-7.
38. Black S, Shinefield HR, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis 2000; 19:187-95.
39. Winston DJ, Schiffman G, Wang D, et al. Pneumococcal infections after human bone-marrow transplantation. Ann Intern Med 1979; 91:835-41.